BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828 clinical trials

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

This study is testing a new medicine, brigimadlin, for people with advanced dedifferentiated liposarcoma. It compares brigimadlin to a standard medicine, doxorubicin, to see if it can slow down or stop the cancer from growing.